11 results on '"Zerbini, Cristiano"'
Search Results
2. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
- Author
-
Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, and Cummings SR
- Subjects
- Absorptiometry, Photon, Aged, Aged, 80 and over, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents pharmacology, Denosumab, Double-Blind Method, Female, Fractures, Bone pathology, Humans, Middle Aged, Placebos, Risk Reduction Behavior, Spinal Fractures pathology, Antibodies, Monoclonal therapeutic use, Bone Density drug effects, Bone Density Conservation Agents therapeutic use, Fractures, Bone prevention & control, Spinal Fractures prevention & control
- Abstract
Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis treatment. We investigated the relevance of DXA BMD changes as a predictor for fracture risk reduction using data from the FREEDOM trial, which randomly assigned placebo or denosumab 60 mg every 6 months to 7808 women aged 60 to 90 years with a spine or total hip BMD T-score < -2.5 and not < -4.0. We took a standard approach to estimate the percent of treatment effect explained using percent changes in BMD at a single visit (months 12, 24, or 36). We also applied a novel approach using estimated percent changes in BMD from baseline at the time of fracture occurrence (time-dependent models). Denosumab significantly increased total hip BMD by 3.2%, 4.4%, and 5.0% at 12, 24, and 36 months, respectively. Denosumab decreased the risk of new vertebral fractures by 68% (p < 0.0001) and nonvertebral fracture by 20% (p = 0.01) over 36 months. Regardless of the method used, the change in total hip BMD explained a considerable proportion of the effect of denosumab in reducing new or worsening vertebral fracture risk (35% [95% confidence interval (CI): 20%-61%] and 51% [95% CI: 39%-66%] accounted for by percent change at month 36 and change in time-dependent BMD, respectively) and explained a considerable amount of the reduction in nonvertebral fracture risk (87% [95% CI: 35% - >100%] and 72% [95% CI: 24% - >100%], respectively). Previous patient-level studies may have underestimated the strength of the relationship between BMD change and the effect of treatment on fracture risk or this relationship may be unique to denosumab., (© 2012 American Society for Bone and Mineral Research)
- Published
- 2012
- Full Text
- View/download PDF
3. [2008 official positions of the Brazilian Society for Clinical Densitometry--SBDens].
- Author
-
Brandão CM, Camargos BM, Zerbini CA, Plapler PG, Mendonça LM, Albergaria BH, Pinheiro MM, Prado Md, and Eis SR
- Subjects
- Adolescent, Adult, Brazil, Child, Female, Humans, Male, Middle Aged, Societies, Medical, Young Adult, Bone Density, Densitometry methods
- Abstract
With the evolution of bone densitometry, differences in technologies, acquisition techniques, reference databases, reporting methods, diagnostic criteria and terminology have developed and the International Society for Clinical Densitometry (ISCD) periodically holds Position Development Conferences, the latest in 2007. The Brazilian Society for Clinical Densitometry (SBDens), with support from many Brazilian societies interested in bone health, gathered numerous specialists to discuss the ISCD proposals and to evaluate the validity of the extension of those norms to Brazilian population. The SBDens reunion of consensus made a very useful document to help the understanding and interpretation of bone densitometry and other methods of bone assessment.
- Published
- 2009
- Full Text
- View/download PDF
4. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
- Author
-
Losada BR, Zanchetta JR, Zerbini C, Molina JF, De la Peña P, Liu CC, Smith RB, Nino AJ, Krohn K, and Warner MR
- Subjects
- Argentina, Brazil, Cohort Studies, Colombia, Double-Blind Method, Female, Glucocorticoids adverse effects, Hispanic or Latino, Humans, Male, Mexico, Middle Aged, Osteoporosis chemically induced, Venezuela, Alendronate pharmacology, Bone Density drug effects, Bone Density Conservation Agents pharmacology, Osteoporosis drug therapy, Osteoporosis ethnology, Teriparatide pharmacology
- Abstract
Glucocorticoid use is a leading cause of secondary osteoporosis. This post hoc analysis compared teriparatide vs alendronate on bone mineral density (BMD) in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis. The 18-mo results from all patients (N=428) in a double-blind trial of teriparatide (20 microg/d) and alendronate (10 mg/d) who had taken glucocorticoids for >or=3 mo were reported (Saag et al. N Engl J Med 2007). The present study analyzed results from the Hispanic (n=61) and non-Hispanic (n=367) cohorts. The BMD was measured by dual-energy X-ray absorptiometry (DXA). In the Hispanic cohort at 18 mo, there were significantly greater increases from baseline in the teriparatide vs alendronate group in lumbar spine BMD (9.8%+/-1.7% vs 4.2%+/-1.4%; p<0.001; mean+/-SE) and total hip BMD (5.9%+/-1.6% vs 1.3%+/-1.3%, p<0.001), with no significant difference between groups at the femoral neck (4.3%+/-2.2% vs 2.0%+/-1.8%, p=0.228). Within each treatment group, the BMD responses were not significantly different in the Hispanic vs non-Hispanic cohort. The number of patients reporting >or=1 adverse event was not significantly different between treatments in either cohort, with more patients reporting nausea in the teriparatide group. In summary, teriparatide was more efficacious than alendronate in increasing BMD in Hispanic and non-Hispanic patients with glucocorticoid-induced osteoporosis. Both treatments were generally well tolerated.
- Published
- 2009
- Full Text
- View/download PDF
5. Dietary intake of Brazilian black and white men and its relationship to the bone mineral density of the femoral neck.
- Author
-
Jaime PC, Latorre Mdo R, Florindo AA, Tanaka T, and Zerbini CA
- Subjects
- Age Factors, Black People, Body Weights and Measures, Brazil, Cross-Sectional Studies, Humans, Linear Models, Male, Middle Aged, Motor Activity, Socioeconomic Factors, White People, Bone Density physiology, Calcium, Dietary administration & dosage, Dietary Proteins administration & dosage, Energy Intake physiology, Femur Neck physiology
- Abstract
Context and Objective: Osteoporosis and fragility fractures are an important public health problem. Although bone loss occurs with age universally, the incidence of bone loss fractures varies greatly between racial groups. The aim of this study was to examine the relationship between calcium, protein and energy intake and the bone mineral density of the femoral neck in Brazilian black and white men., Design and Setting: This was a cross-sectional study, carried out in a teaching hospital in São Paulo., Methods: The participants were 277 volunteer men, aged 50 years or older. The bone mineral density of the femoral neck (FNBMD) was measured by dual energy x-ray absorptiometry. The relationship between FNBMD and calcium, protein and energy intake, as assessed by a three-day food record, was analyzed using multiple linear regression models and was adjusted for age, height, physical activity and education level. The analysis was stratified by race (white and black)., Results: FNBMD presented similar means in the two racial groups (p = 0.538). Protein and energy intake did not show a significant correlation with FNBMD, either in the white or in the black population. Calcium intake showed a strong and independent correlation with FNBMD in the black men (partial r = 0.42)., Conclusion: Calcium intake was a determinant of FNBMD for black men, aged 50 years or older, but not for the white ones.
- Published
- 2006
- Full Text
- View/download PDF
6. Past and present habitual physical activity and its relationship with bone mineral density in men aged 50 years and older in Brazil.
- Author
-
Florindo AA, Latorre Mdo R, Jaime PC, Tanaka T, Pippa MG, and Zerbini CA
- Subjects
- Age Factors, Aged, Aged, 80 and over, Body Mass Index, Brazil epidemiology, Cross-Sectional Studies, Humans, Linear Models, Male, Middle Aged, Sex Factors, Statistics as Topic, Bone Density physiology, Exercise physiology
- Abstract
Background: The aim of this study was to determine the relationship between habitual physical activity (HPA) during life and bone mineral density (BMD) in men aged 50 years and older., Methods: A total of 326 men aged 50 years and older, volunteers living in São Paulo city, Brazil, were studied. BMD was measured in the whole body, femoral neck, Ward's triangle, trochanter, and lumbar spine (L2-L4) with a dual-energy x-ray absorptiometer. The HPA data were collected with questionnaires inquiring about physical exercise and occupational physical activity in the past and during the past 12 months and leisure and locomotor physical activity in the preceding 12 months. The relationship between BMD and HPA was analyzed using multiple linear regression models adjusted for age and body mass index (BMI)., Results: Practice of physical exercise in the past 10-20 years and leisure and locomotor physical activity in the preceding 12 months showed a significant positive correlation with BMD of whole body, femoral neck, trochanter, and lumbar spine, and this association was independent of age and BMI., Conclusions: HPA can contribute to preserving BMD in men aged 50 years and older in Brazil, when it is practiced in the past 10-20 years and even in the present.
- Published
- 2002
- Full Text
- View/download PDF
7. Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)
- Author
-
Messina, Osvaldo Daniel, Vidal, Maritza, Torres, Jorge A Morales, Vidal, Luis Fernando, Arguissain, Constanza, Pereira, Rosa María, Clark, Patricia, Cerdas Perez, Sonia, Campusano, Claudia, Lazaretti-Castro, Marise, Zerbini, Cristiano, Scali, Juan J., Mendez Sanchez, Lucia, Peralta-Pedrero, Maria L., Cavallo, Andrea, Valdivia Ibarra, Francisco J., and Hernandez Pérez, Talina
- Published
- 2022
- Full Text
- View/download PDF
8. Chronic arthritides and bone structure: focus on rheumatoid arthritis—an update.
- Author
-
Messina, Osvaldo Daniel, Vidal, Maritza, Adami, Giovanni, Vidal, Luis Fernando, Clark, Patricia, Torres, Jorge A. Morales, Lems, William, Zerbini, Cristiano, Arguissain, Constanza, Reginster, Jean-Yves, and Lane, Nancy E.
- Subjects
CYTOKINES ,GLUCOCORTICOIDS ,BONES ,INFECTIOUS arthritis ,OSTEOCLASTS ,BONE resorption ,INFLAMMATION ,OSTEOBLASTS ,ACTIVITIES of daily living ,OSTEOPOROSIS ,RHEUMATOID arthritis ,BONE remodeling ,BONE density ,VITAMIN D deficiency ,BONE fractures ,DISEASE risk factors - Abstract
Normal bone remodeling depends of a balance between bone forming cells, osteoblasts and bone resorbing cells, the osteoclasts. In chronic arthritides and some inflammatory and autoimmune diseases such as rheumatoid arthritis, there is a great constellation of cytokines produced by pannus that impair bone formation and stimulate bone resorption by inducing osteoclast differentiation and inhibiting osteoblast maturation. Patients with chronic inflammation have multiple causes that lead to low bone mineral density, osteoporosis and a high risk of fracture including circulating cytokines, impaired mobility, chronic administration of glucocorticoids, low vitamin D levels and post-menopausal status in women, among others. Biologic agents and other therapeutic measures to reach prompt remission might ameliorate these deleterious effects. In many cases, bone acting agents need to be added to conventional treatment to reduce the risk of fractures and to preserve articular integrity and independency for daily living activities. A limited number of studies related to fractures in chronic arthritides were published, and future investigation is needed to determine the risk of fractures and the protective effects of different treatments to reduce this risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
- Author
-
Miller, Paul D., Hattersley, Gary, Riis, Bente Juel, Williams, Gregory C., Lau, Edith, Russo, Luis Augusto, Alexandersen, Peter, Zerbini, Cristiano A. F., Ming-yi Hu, Harris, Alan G., Fitzpatrick, Lorraine A., Cosman, Felicia, Christiansen, Claus, Hu, Ming-yi, and ACTIVE Study Investigators
- Subjects
OSTEOPOROSIS ,BONE fractures ,PARATHYROID hormone ,POSTMENOPAUSE ,FEMUR injuries ,SPINAL injuries ,THORACIC vertebrae injuries ,PLACEBOS ,BONE fracture prevention ,SUBCUTANEOUS injections ,COMPARATIVE studies ,DIPHOSPHONATES ,FEMUR neck ,HYPERCALCEMIA ,LUMBAR vertebrae ,RESEARCH methodology ,MEDICAL cooperation ,PELVIC bones ,PEPTIDE hormones ,RESEARCH ,EVALUATION research ,BONE density ,RANDOMIZED controlled trials ,BLIND experiment ,PHYSIOLOGY ,TERIPARATIDE ,PREVENTION ,THERAPEUTICS ,WOUNDS & injuries - Abstract
Importance: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.Objective: To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in postmenopausal women at risk of osteoporotic fracture.Design, Setting, and Participants: The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) was a phase 3, double-blind, RCT (March 2011-October 2014) at 28 sites in 10 countries. Postmenopausal women with bone mineral density (BMD) T score ≤-2.5 and >-5.0 at the lumbar spine or femoral neck and radiological evidence ≥2 mild or ≥1 moderate lumbar or thoracic vertebral fracture or history of low-trauma nonvertebral fracture within the past 5 years were eligible. Postmenopausal women (>65 y) with fracture criteria and a T score ≤-2.0 and >-5.0 or without fracture criteria and a T score ≤-3.0 and >-5.0 could enroll.Interventions: Blinded, daily subcutaneous injections of placebo (n = 821); abaloparatide, 80 μg (n = 824); or open-label teriparatide, 20 μg (n = 818) for 18 months.Main Outcomes and Measures: Primary end point was percentage of participants with new vertebral fracture in the abaloparatide vs placebo groups. Sample size was set to detect a 4% difference (57% risk reduction) between treatment groups. Secondary end points included change in BMD at total hip, femoral neck, and lumbar spine in abaloparatide-treated vs placebo participants and time to first incident nonvertebral fracture. Hypercalcemia was a prespecified safety end point in abaloparatide-treated vs teriparatide participants.Results: Among 2463 women (mean age, 69 years [range, 49-86]), 1901 completed the study. New morphometric vertebral fractures occurred less frequently in the active treatment groups vs placebo. The Kaplan-Meier estimated event rate for nonvertebral fracture was lower with abaloparatide vs placebo. BMD increases were greater with abaloparatide than placebo (all P < .001). Incidence of hypercalcemia was lower with abaloparatide (3.4%) vs teriparatide (6.4%) (risk difference [RD], −2.96 [95%CI, −5.12 to −0.87]; P = .006). [table: see text].Conclusions and Relevance: Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed to understand the clinical importance of RD, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments.Trial Registration: clinicaltrials.gov Identifier: NCT01343004. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
- Author
-
Kendler, David L., Marin, Fernando, Zerbini, Cristiano A. F., Russo, Luis A., Greenspan, Susan L., Zikan, Vit, Bagur, Alicia, Malouf-Sierra, Jorge, Lakatos, Péter, Fahrleitner-Pammer, Astrid, Lespessailles, Eric, Minisola, Salvatore, Body, Jean Jacques, Geusens, Piet, Möricke, Rüdiger, and López-Romero, Pedro
- Subjects
- *
OSTEOPOROSIS in women , *RISK factors of fractures , *TERIPARATIDE , *RISEDRONATE , *POSTMENOPAUSE , *OSTEOPOROSIS treatment , *THERAPEUTICS , *COMPARATIVE studies , *DIPHOSPHONATES , *RESEARCH methodology , *MEDICAL cooperation , *OSTEOPOROSIS , *RADIOGRAPHY , *RESEARCH , *EVALUATION research , *BONE density , *RANDOMIZED controlled trials , *DISEASE incidence , *BLIND experiment , *DISEASE complications - Abstract
Background: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.Methods: In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1·50. Participants were randomly assigned to receive 20 μg of teriparatide once daily plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo for 24 months. The primary outcome was new radiographic vertebral fractures. Secondary, gated outcomes included new and worsened radiographic vertebral fractures, clinical fractures (a composite of non-vertebral and symptomatic vertebral), and non-vertebral fractures. This study is registered with ClinicalTrials.gov (NCT01709110) and EudraCT (2012-000123-41).Findings: We enrolled 680 patients in each group. At 24 months, new vertebral fractures occurred in 28 (5·4%) of 680 patients in the teriparatide group and 64 (12·0%) of 680 patients in the risedronate group (risk ratio 0·44, 95% CI 0·29-0·68; p<0·0001). Clinical fractures occurred in 30 (4·8%) of 680 patients in the teriparatide group compared with 61 (9·8%) of 680 in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Interpretation: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Funding: Lilly. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
- Author
-
Cosman, Felicia, Crittenden, Daria B., Adachi, Jonathan D., Binkley, Neil, Czerwinski, Edward, Ferrari, Serge, Hofbauer, Lorenz C., Lau, Edith, Lewiecki, E. Michael, Miyauchi, Akimitsu, Zerbini, Cristiano A. F., Milmont, Cassandra E., Li Chen, Maddox, Judy, Meisner, Paul D., Libanati, Cesar, Grauer, Andreas, and Chen, Li
- Subjects
- *
SCLEROSTIN , *BONE morphogenetic proteins , *BONE resorption , *MONOCLONAL antibody probes , *PLACEBOS , *THERAPEUTIC use of monoclonal antibodies , *BONE fracture prevention , *BONE remodeling , *SUBCUTANEOUS injections , *COMPARATIVE studies , *BONE fractures , *DIPHOSPHONATES , *RESEARCH methodology , *MEDICAL cooperation , *MONOCLONAL antibodies , *OSTEOPOROSIS , *RESEARCH , *STATISTICAL sampling , *EVALUATION research , *SPINAL injuries , *BONE density , *RANDOMIZED controlled trials , *BLIND experiment , *PREVENTION - Abstract
Background: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption.Methods: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab for 12 months, at a dose of 60 mg, administered subcutaneously every 6 months. The coprimary end points were the cumulative incidences of new vertebral fractures at 12 months and 24 months. Secondary end points included clinical (a composite of nonvertebral and symptomatic vertebral) and nonvertebral fractures.Results: At 12 months, new vertebral fractures had occurred in 16 of 3321 patients (0.5%) in the romosozumab group, as compared with 59 of 3322 (1.8%) in the placebo group (representing a 73% lower risk with romosozumab; P<0.001). Clinical fractures had occurred in 58 of 3589 patients (1.6%) in the romosozumab group, as compared with 90 of 3591 (2.5%) in the placebo group (a 36% lower risk with romosozumab; P=0.008). Nonvertebral fractures had occurred in 56 of 3589 patients (1.6%) in the romosozumab group and in 75 of 3591 (2.1%) in the placebo group (P=0.10). At 24 months, the rates of vertebral fractures were significantly lower in the romosozumab group than in the placebo group after each group made the transition to denosumab (0.6% [21 of 3325 patients] in the romosozumab group vs. 2.5% [84 of 3327] in the placebo group, a 75% lower risk with romosozumab; P<0.001). Adverse events, including instances of hyperostosis, cardiovascular events, osteoarthritis, and cancer, appeared to be balanced between the groups. One atypical femoral fracture and two cases of osteonecrosis of the jaw were observed in the romosozumab group.Conclusions: In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.